Home Journal Club	FAQ My Amedeo About Tranquillis Services	Flying Publisher
	Books, Journals, Podcasts, Weekly Updates, by Amedeo

Breast Cancer

Free Subscription Articles published in Cancer Chemother Pharmacol Retrieve available abstracts of 33 articles: HTML format Text format

Single Articles

March 2010
1. DAVOLI A , Hocevar BA, Brown TL
   Progression and treatment of HER2-positive breast cancer.
   Cancer Chemother Pharmacol. 2010;65:611-23.
   PubMed     Text format     Related articles    Abstract available
   
   
   February 2010
2. ANTOON JW , Liu J, Ponnapakkam AP, Gestaut MM, et al
   Novel D: -erythro N-octanoyl sphingosine analogs as chemo- and endocrine-resistant breast cancer therapeutics.
   Cancer Chemother Pharmacol. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   December 2009
3. MOON YW , Sohn JH, Choi HJ, Chang H, et al
   Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.
   Cancer Chemother Pharmacol. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
4. REINICKE KE , Kuffel MJ, Goetz MP, Ames MM, et al
   Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells.
   Cancer Chemother Pharmacol. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
5. WANG Y , Rishi AK, Puliyappadamba VT, Sharma S, et al
   Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.
   Cancer Chemother Pharmacol. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
6. PARK YH , Lee S, Cho EY, Choi YL, et al
   Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.
   Cancer Chemother Pharmacol. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   October 2009
7. LIU S , Monks NR, Hanes JW, Begley TP, et al
   Sensitivity of breast cancer cell lines to recombinant thiaminase I.
   Cancer Chemother Pharmacol. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
8. KURTZBERG LS , Roth SD, Bagley RG, Rouleau C, et al
   Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents.
   Cancer Chemother Pharmacol. 2009;64:1029-38.
   PubMed     Text format     Related articles    Abstract available
   
   
   September 2009
9. VAULEON E , Mesbah H, Laguerre B, Gedouin D, et al
   Usefulness of chemotherapy beyond the second line for metastatic breast cancer: a therapeutic challenge.
   Cancer Chemother Pharmacol. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
10. PRADOS J , Melguizo C, Rama AR, Ortiz R, et al
    Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
11. MASUDA N , Nakayama T, Yamamura J, Kamigaki S, et al
    Phase I study of combination therapy with weekly paclitaxel and cyclophosphamide for advanced or recurrent breast cancer.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    August 2009
12. PLEDGIE-TRACY A , Billam M, Hacker A, Sobolewski MD, et al
    The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
13. ROCCA A , Maltoni R, Passardi A, Massa I, et al
    A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
14. JONES A , O'Brien M, Sommer H, Nowara E, et al
    Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
15. SIMS JT , Plattner R
    MTT assays cannot be utilized to study the effects of STI571/Gleevec on the viability of solid tumor cell lines.
    Cancer Chemother Pharmacol. 2009;64:629-33.
    PubMed     Text format     Related articles    Abstract available
    
    
    
16. FURUYA Y , Yanagie H, Wakahara T, Mishina Y, et al
    Improved survival in patients with breast rhabdoid tumors with multi-agent adjuvant chemotherapy combined with irradiation.
    Cancer Chemother Pharmacol. 2009;64:623-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    July 2009
17. OZBAY T , Durden DL, Liu T, O'Regan RM, et al
    In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
18. DENT SF , Gertler S, Verma S, Segal R, et al
    A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
19. ABU AJAJ K , Graeser R, Fichtner I, Kratz F, et al
    In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B.
    Cancer Chemother Pharmacol. 2009;64:413-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
20. ISHIDA T , Kiba T, Takeda M, Matsuyama K, et al
    Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.
    Cancer Chemother Pharmacol. 2009;64:361-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    June 2009
21. NIETO Y , Aramendia JM, Espinos J, De la Cruz S, et al
    Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
22. ENDO M , Miwa M, Ura M, Tanimura H, et al
    A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    May 2009
23. DU G , Lin H, Wang M, Zhang S, et al
    Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1alpha in tumor and normal cells.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
24. WATERS SH , Gillibrand A, Berry H, Kumar S, et al
    Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
25. KUREBAYASHI J , Nukatsuka M, Sonoo H, Uchida J, et al
    Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
26. AKIYOSHI T , Matzno S, Sakai M, Okamura N, et al
    The potential of vitamin K(3) as an anticancer agent against breast cancer that acts via the mitochondria-related apoptotic pathway.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    April 2009
27. JOBSON AG , Willmore E, Tilby MJ, Mistry P, et al
    Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases.
    Cancer Chemother Pharmacol. 2009;63:889-901.
    PubMed     Text format     Related articles    Abstract available
    
    
    
28. STOEGER SM , Cowan KH
    Characterization of kinase suppressor of Ras-1 expression and anticancer drug sensitivity in human cancer cell lines.
    Cancer Chemother Pharmacol. 2009;63:807-18.
    PubMed     Text format     Related articles    Abstract available
    
    
    
29. BAR-SELA G , Haim N
    Uncontrolled hypertriglyceridemia induced by capecitabine: case report and review of the literature.
    Cancer Chemother Pharmacol. 2009;63:779-82.
    PubMed     Text format     Related articles    Abstract available
    
    
    March 2009
30. RIXE O , Franco SX, Yardley DA, Johnston SR, et al
    A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    February 2009
31. RUFF P , Vorobiof DA, Jordaan JP, Demetriou GS, et al
    A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    January 2009
32. NOLE F , Crivellari D, Mattioli R, Pinotti G, et al
    Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
33. BOZIONELOU V , Kalbakis K, Vamvakas L, Agelaki S, et al
    A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: